Type 2 Diabetes and Exercise—Where Do We Stand?
Saturday, June 22, at 8:00 a.m. ET
Room W314
Orange County Convention Center
Incretin-Based Pharmacotherapy, (Osteo)sarcopenia, and Exercise
Samuel Klein, MD
Director, Center for Human Nutrition,
Washington University School of Medicine
What is your presentation about?
The marked weight loss induced by incretin-based pharmacotherapy and the results from several trials that found a large portion of the lost weight was comprised of fat-free mass/lean body mass have led to a concern that this therapy has adverse effects on physical function and can even cause physical frailty.
How do you hope your presentation will impact diabetes research or care?
This presentation will review: 1) whether the decrease in muscle mass associated with marked weight loss in people with obesity and diabetes is clinically relevant; and 2) interventions that can attenuate the weight loss induced decrease in muscle mass.
How did you become involved with this area of diabetes research or care?
A component of our research program is trying to understand why weight loss in people with obesity and prediabetes/diabetes has such profound therapeutic effects on metabolic function. As part of this research we study people with obesity and prediabetes/diabetes before and after marked weight loss induced by intensive lifestyle therapy or bariatric surgery.